Volume 54, Issue 2, Pages 382-391 (August 2008) Continuous versus Six Months a Year Maximal Androgen Blockade in the Management of Prostate Cancer: A Randomised Study  Jacques Irani, Olivier Celhay, Jacques Hubert, Franck Bladou, Evelyne Ragni, Gérard Trape, Bertrand Doré  European Urology  Volume 54, Issue 2, Pages 382-391 (August 2008) DOI: 10.1016/j.eururo.2008.02.024 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Mean testosterone values at months (M) 0, 3, 6, 12, 18, 24, 30, 36, 42, and 48. Difference is significant between the CAS (black dots) and SIAS (white dots) groups at M12 (Mann-Whitney U test, p<0.0001), M24 (p=0.003) and M36 (p=0.04). CAS, continuous androgen suppression; SIAS, systematically interrupted androgen suppression. European Urology 2008 54, 382-391DOI: (10.1016/j.eururo.2008.02.024) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Mean scores of EORTC QLQ C-30 scales according to randomisation arm (CAS: black dots and SIAS: white dots) at M0, M6, M12, and M24. Bars indicate the 95% confidence intervals. (a) Optimal scores are rated 100. Last observation score was significantly lower than baseline for XPF, XRF, XEF, XCF without significant difference between the two groups. (b) Absence of symptom is rated 0. Last observation score was significantly higher than baseline for sleep disturbance and fatigue without significant difference between the two groups. EORTC, European Organization for Research and Treatment of Cancer; CAS, continuous androgen suppression; SIAS, systematically interrupted androgen suppression; XPF, physical functioning; XRF, role functioning; XEF, emotional functioning; XCF, cognitive functioning; XSF, social functioning; XQL, quality of Life; XNV, nausea vomiting; XPA, pain; XDY, dyspnea; XSL, sleep disturbance; XAP, appetite; XCO, constipation; XDI, diarrhea; XFA, fatigue. European Urology 2008 54, 382-391DOI: (10.1016/j.eururo.2008.02.024) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Mean scores of EORTC QLQ C-30 scales according to randomisation arm (CAS: black dots and SIAS: white dots) at M0, M6, M12, and M24. Bars indicate the 95% confidence intervals. (a) Optimal scores are rated 100. Last observation score was significantly lower than baseline for XPF, XRF, XEF, XCF without significant difference between the two groups. (b) Absence of symptom is rated 0. Last observation score was significantly higher than baseline for sleep disturbance and fatigue without significant difference between the two groups. EORTC, European Organization for Research and Treatment of Cancer; CAS, continuous androgen suppression; SIAS, systematically interrupted androgen suppression; XPF, physical functioning; XRF, role functioning; XEF, emotional functioning; XCF, cognitive functioning; XSF, social functioning; XQL, quality of Life; XNV, nausea vomiting; XPA, pain; XDY, dyspnea; XSL, sleep disturbance; XAP, appetite; XCO, constipation; XDI, diarrhea; XFA, fatigue. European Urology 2008 54, 382-391DOI: (10.1016/j.eururo.2008.02.024) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier survival curves according to group. In all cases, the difference between CAS (solid line) and SIAS (dotted line) was not significant. (a) Progression free survival (log-rank test, p=0.3). (b) Specific survival (log-rank test, p=0.12). (c) Overall survival (log-rank test, p=0.06). CAS, continuous androgen suppression; SIAS, systematically interrupted androgen suppression. European Urology 2008 54, 382-391DOI: (10.1016/j.eururo.2008.02.024) Copyright © 2008 European Association of Urology Terms and Conditions